Ista drops 31% and looks to EAST as Remura goes WEST in late-stage dry eye trial
This article was originally published in Scrip
Ista Pharmaceuticals has suffered a setback in its plans for its latest extension of its bromfenac sodium franchise. It revealed that its lower concentration of bromfenac, Remura (bromfenac ophthalmic), missed the co-primary endpoints of improving one sign and one symptom of dry eye disease at day 42 versus placebo in the first of two Phase III studies. Ista shares fell $2.23, or 31%, to $4.97 in late trading on 29 July.